To assess the therapeutic value of BPTF inhibition during PDA progression, we used a KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; and Pdx1-Cre (KPC)-derived cell lines) syngeneic mouse model of pancreatic ductal adenocarcinoma (PDA) that recapitulates the human disease. This evidence concerns the gene BPTF and pancreatic ductal adenocarcinoma.